Document is current
Any future updates will be listed below
-
Authors
Miranda, Marcos C. https://orcid.org/0000-0002-2839-6997
Kepl, Elizabeth
Navarro, Mary Jane
Chen, Chengbo https://orcid.org/0000-0002-3459-3655
Johnson, Max
Sprouse, Kaitlin R. https://orcid.org/0000-0003-0007-2226
Stewart, Cameron
Palser, Anne
Valdez, Adian https://orcid.org/0009-0007-3772-9646
Pettie, Deleah
Sydeman, Claire
Ogohara, Cassandra
Kraft, John C.
Pham, Minh
Murphy, Michael
Wrenn, Sam
Fiala, Brooke
Ravichandran, Rashmi
Ellis, Daniel
Carter, Lauren
Corti, Davide
Kellam, Paul
Lee, Kelly
Walls, Alexandra C.
Veesler, David
King, Neil P. https://orcid.org/0000-0002-2978-4692
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01AI167966)
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 25 September 2024
First Online: 8 October 2024
Competing interests
: A.C.W., D.E., D.V., and N.P.K. are named as inventors on patent applications filed by the University of Washington based on the studies presented in this paper. The King lab has received unrelated sponsored research agreements from Pfizer and GSK. D.V. is a consultant for and has received an unrelated sponsored research agreement from Vir Biotechnology Inc. P.K. and A.P. were employees and shareholders of Kymab Ltd, now Kymab, a Sanofi Company. The other authors declare no competing interests.
